LC
RPRX icon

Lindbrook Capital’s Royalty Pharma RPRX Stock Holding History

Lindbrook Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$29.2K Sell
938
-509
-35% -$16.1K ﹤0.01% 1197
2024
Q4 		$36.9K Buy
1,447
+316
+28% +$8.38K ﹤0.01% 948
2024
Q3 		$32K Sell
1,131
-697
-38% -$19.3K ﹤0.01% 1030
2024
Q2 		$48.2K Sell
1,828
-572
-24% -$15.9K ﹤0.01% 809
2024
Q1 		$72.9K Sell
2,400
-11
-0.5% -$324 0.01% 645
2023
Q4 		$67.7K Buy
2,411
+1,999
+485% +$54.9K 0.01% 655
2023
Q3 		$11.2K Buy
412
+136
+49% +$4.04K ﹤0.01% 1354
2023
Q2 		$8.48K Sell
276
-198
-42% -$6.71K ﹤0.01% 1568
2023
Q1 		$17.1K Buy
474
+451
+1,961% +$16.7K ﹤0.01% 1149
2022
Q4 		$909 Buy
23
+13
+130% +$543 ﹤0.01% 2483
2022
Q3 		$0 Sell
10
-169
-94% -$7.22K ﹤0.01% 2870
2022
Q2 		$8K Buy
179
+154
+616% +$6.31K ﹤0.01% 1361
2022
Q1 		$1K Buy
+25
New +$982 ﹤0.01% 2341

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Lindbrook Capital's RPRX Position: Q1 2025 in Review

Lindbrook Capital reduced its Royalty Pharma (RPRX) stake by 35% in Q1 2025, selling an estimated $16.1K and leaving 938 shares worth $29.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1197.

Lindbrook Capital first reported a position in RPRX in Q1 2022 and has held it in 13 quarters since. The position peaked at $72.9K in Q1 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

  • Lindbrook Capital held 938 shares of Royalty Pharma worth $29.2K as of Q1 2025.
  • Lindbrook Capital sold 509 Royalty Pharma shares in Q1 2025, an estimated $16.1K.
  • Royalty Pharma made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1197 holding.
  • Lindbrook Capital first reported a position in Royalty Pharma in Q1 2022 and has held it in 13 quarters since.
  • Lindbrook Capital's Royalty Pharma position peaked at $72.9K in Q1 2024.
  • 447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.